Novorapid (Insulin Aspart)

Insulin aspart contains two amino‑acid changes that prevent self‑aggregation, allowing it to be absorbed quickly after subcutaneous injection. It binds to insulin receptors, activating intracellular pathways that increase glucose uptake in muscle and fat and suppress hepatic glucose production, thereby lowering blood sugar.

The dose of Novorapid is individualized by the prescribing healthcare professional based on factors such as the patient’s blood glucose targets, carbohydrate intake, current insulin regimen, renal function, and overall health. No fixed dosing schedule is provided; the prescriber calculates the appropriate amount.

Insulin aspart is classified as a pregnancy‑category B medication, meaning it is generally considered safe when used under medical supervision. It does pass into breast milk in small amounts, but the benefits of controlling maternal blood glucose usually outweigh potential risks to the infant.

To order Novorapid, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and import documentation.

Novorapid shares a similar onset and duration of action with other rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose reduction, while individual patient response, formulation preferences, and device compatibility may influence the choice of product.

Novorapid should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial or cartridge. Once in use, the product may remain at room temperature for a limited period as specified in the package insert.

Novorapid is administered by subcutaneous injection, typically using an insulin pen, syringe, or insulin pump. It is injected into the abdomen, thigh, upper arm, or buttock shortly before meals, usually within 5–10 minutes, to match the rise in blood glucose after eating.

The most serious risks include severe hypoglycemia, which can cause seizures, loss of consciousness, or require emergency assistance, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of low blood sugar and have a plan for prompt treatment.

Novorapid should be avoided in individuals with a known hypersensitivity to insulin aspart or any of its excipients. It is also contraindicated in patients with severe hypoglycemia unawareness or those who cannot reliably monitor blood glucose levels. Clinical judgment is required for use in certain critical illnesses.